会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Graft-versus-host disease predicting marker and use thereof
    • 移植物抗宿主病预测标记及其用途
    • US08603754B2
    • 2013-12-10
    • US13204799
    • 2011-08-08
    • Akira ShibuyaHiroshi Kojima
    • Akira ShibuyaHiroshi Kojima
    • G01N33/53
    • G01N33/573A61K39/3955A61K2039/505C07K16/2803G01N2333/91245G01N2800/245
    • A test method that provides data useful in predicting the probability of onset of acute graft-versus-host disease (GVHD) is described along with a kit for performing the method, and a pharmaceutical preparation and a molecular targeted therapy for treating or preventing GVHD. The test method includes measuring the blood DNAM-1 concentration of a patient of hematopoietic stem cell transplantation from bone marrow or the like over a period after the transplantation to provide data concerning the transition of the concentration to an abnormally high level deviating from the normal range, whereby the probability of the development of acute graft-versus-host disease is predicted, the risk of the development is estimated, or therapeutic effects after the development are evaluated. Concerning the molecular targeted therapy and pharmaceutical preparation used therefor wherein blood DNAM-1 of a GVHD patient or a graft recipient that is a possible patient is used as a target molecule, GVHD is treated or prevented by administering an anti-DNAM-1 antibody that is a neutralizing antibody.
    • 描述了提供用于预测急性移植物抗宿主病(GVHD)发病概率的数据的测试方法以及用于进行该方法的试剂盒以及用于治疗或预防GVHD的药物制剂和分子靶向治疗。 测试方法包括在移植后的一段时间内测量来自骨髓等的造血干细胞移植患者的血液DNAM-1浓度,以提供关于浓度向偏离正常范围的异常高水平转变的数据 预测急性移植物抗宿主病发展的可能性,估计发展的风险,或发展后的治疗效果。 关于其中使用的分子靶向治疗和药物制剂,其中GVHD患者的血液DNAM-1或作为可能患者的移植物接受体用作靶分子,通过施用抗-DNAM-1抗体来治疗或预防GVHD, 是中和抗体。
    • 2. 发明授权
    • Method for producing β-mercapto carboxylic acids
    • - 巯基羧酸的生产方法
    • US08258340B2
    • 2012-09-04
    • US12921495
    • 2009-03-11
    • Hidemasa AokiAkio KuroiwaAkira Shibuya
    • Hidemasa AokiAkio KuroiwaAkira Shibuya
    • C07B53/00
    • C07C319/04C07C323/56C07C323/52
    • An object of the present invention is to provide a method for industrially producing β-mercapto carboxylic acids that are useful as synthetic raw materials for medicines and agrochemicals or as additives for polymer compounds from easily available α,β-unsaturated carboxylic acids in high yields and productivity.The present invention is characterized in that a solvent having an amide group and represented by the formula (1) is used when the α,β-unsaturated carboxylic acids are reacted with hydrogen sulfides to produce the β-mercapto carboxylic acids. Particularly, it is more preferable to carry out the reaction at a pH range of 6.0 to 8.5: (In the formula (1), R1 represents any one of a hydrogen atom, an alkoxy group having 1 to 5 carbon atoms, an alkyl group having 1 to 5 carbon atoms, an amino group, and an alkylamino group having 1 to 5 carbon atoms; R2 and R3 each represents independently any one of a hydrogen atom and an alkyl group having 1 to 5 carbon atoms; when both R2 and R3 are not a hydrogen atom, R2 and R3 may together form a ring structure through an alkylene group; and when both R1 and R2 are not a hydrogen atom, R1 and R2 may form a ring structure through an alkylene group).
    • 本发明的一个目的是提供一种工业上生产和/或巯基羧酸的方法,其可用作药物和农用化学品的合成原料或作为高分子化合物的添加剂,其易于获得的α,β-不饱和羧酸在高 产量和生产力。 本发明的特征在于,当α,bgr-不饱和羧酸与硫化氢反应以制备β-巯基羧酸时,使用具有酰胺基并由式(1)表示的溶剂。 特别优选在6.0〜8.5的pH范围进行反应(式(1)中,R 1表示氢原子,碳原子数1〜5的烷氧基,烷基 具有1至5个碳原子,氨基和具有1至5个碳原子的烷基氨基; R 2和R 3各自独立地表示氢原子和具有1至5个碳原子的烷基中的任一个;当R 2和R 3均为 不是氢原子,R2和R3可以一起通过亚烷基形成环结构;当R1和R2都不是氢原子时,R1和R2可以通过亚烷基形成环结构)。
    • 3. 发明申请
    • Graft-Versus-Host Disease Predicting Marker and Use Thereof
    • 移植物抗宿主病预测标记及其用途
    • US20110318762A1
    • 2011-12-29
    • US13204799
    • 2011-08-08
    • Akira ShibuyaHiroshi Kojima
    • Akira ShibuyaHiroshi Kojima
    • G01N33/577
    • G01N33/573A61K39/3955A61K2039/505C07K16/2803G01N2333/91245G01N2800/245
    • A test method that provides data useful in predicting the probability of onset of acute graft-versus-host disease (GVHD) is described along with a kit for performing the method, and a pharmaceutical preparation and a molecular targeted therapy for treating or preventing GVHD. The test method includes measuring the blood DNAM-1 concentration of a patient of hematopoietic stem cell transplantation from bone marrow or the like over a period after the transplantation to provide data concerning the transition of the concentration to an abnormally high level deviating from the normal range, whereby the probability of the development of acute graft-versus-host disease is predicted, the risk of the development is estimated, or therapeutic effects after the development are evaluated. Concerning the molecular targeted therapy and pharmaceutical preparation used therefor wherein blood DNAM-1 of a GVHD patient or a graft recipient that is a possible patient is used as a target molecule, GVHD is treated or prevented by administering an anti-DNAM-1 antibody that is a neutralizing antibody.
    • 描述了提供用于预测急性移植物抗宿主病(GVHD)发病概率的数据的测试方法以及用于进行该方法的试剂盒以及用于治疗或预防GVHD的药物制剂和分子靶向治疗。 测试方法包括在移植后的一段时间内测量来自骨髓等的造血干细胞移植患者的血液DNAM-1浓度,以提供关于浓度向偏离正常范围的异常高水平转变的数据 预测急性移植物抗宿主病发展的可能性,估计发展的风险,或发展后的治疗效果。 关于其中使用的分子靶向治疗和药物制剂,其中GVHD患者的血液DNAM-1或作为可能患者的移植物接受体用作靶分子,通过施用抗-DNAM-1抗体来治疗或预防GVHD, 是中和抗体。
    • 6. 发明申请
    • METHOD FOR PRODUCING B-MERCAPTOCARBOXYLIC ACIDS
    • 生产β-巯基羧酸的方法
    • US20110004017A1
    • 2011-01-06
    • US12677251
    • 2008-09-19
    • Akira ShibuyaHidemasa Aoki
    • Akira ShibuyaHidemasa Aoki
    • C07B53/00
    • C07C319/04C07B45/06C07C2601/10C07C2601/16C07C323/52C07C323/56
    • The invention relates to a method for efficiently producing β-mercaptocarboxylic acids using a solid acid catalyst such as zeolite, which product corresponds to respective starting materials selected from α,β-unsaturated carboxylic acids (α,β-unsaturated carboxylic acid, α,β-unsaturated carboxylic acid ester, α,β-unsaturated amide, α,β-unsaturated aldehide and α,β-unsaturated ketone) and hydrogen sulfides (hydrogen sulfide, sulfide salt and hydrosulfide salt), wherein a solvent compatible with water is used in the reaction. According to the invention, β-mercaptocarboxylic acids which are useful as additives in synthetic materials for pharmaceutical or agricultural agents and in polymer compounds can be industrially produced efficiently by using easily available α,β-unsaturated carboxylic acid (such as crotonic acid) at high yield.
    • 本发明涉及一种使用固体酸催化剂如沸石有效生产β-巯基羧酸的方法,该产物对应于选自α,β-不饱和羧酸(α,β-不饱和羧酸, α,β-不饱和羧酸酯,α,bgr-不饱和酰胺,α,bgr-不饱和醛和α,bgr-不饱和酮)和硫化氢(硫化氢,硫化物盐和氢硫化物盐),其中a 在反应中使用与水相容的溶剂。 根据本发明,可用作药物或农药合成材料和聚合物化合物的合成材料中的添加剂的β-巯基羧酸可以通过使用容易获得的α,β-不饱和羧酸(例如巴豆酸)工业上有效地生产, 以高产量。
    • 7. 发明授权
    • Halftone image ion printer
    • 半色调图像离子打印机
    • US5687001A
    • 1997-11-11
    • US7143
    • 1993-01-21
    • Akira ShibuyaHiroyuki KadowakiTomohiro ShinboMasayuki Iijima
    • Akira ShibuyaHiroyuki KadowakiTomohiro ShinboMasayuki Iijima
    • H04N1/40G01D15/06
    • H04N1/40043H04N1/40056H04N1/40081
    • The invention makes it possible to drive a halftone image device and achieve high halftone reproduction by allowing at least one of the leading and trailing edges of a pulse width-modulated signal applied to a recording head, or forming amplitude- and width-modulated pulses, respectively, as driving pulses for placing one dot under halftone control, and changing pulse width modulation in a stepwise manner, using the pulse width of the amplitude-modulated pulse as a unit pulse width. The invention intends to achieve high-voltage and high-speed pulse output and low power consumption by converting input data such as halftone image data to a voltage signal, superposing pulse voltages of opposite polarities and applying the resulting signal to a switching circuit constituting an output state in the form of a switching signal, and also makes it possible to achieve high speed and high-voltage driving by connecting at least one of equivalent two-terminal elements in series to at least one of the respective driving elements of a complementary FET driving circuit, said equivalent two-terminal elements are each turned on with a current of a certain or higher value passing therethrough to show constant-voltage characteristics and turned off with a current of a certain or lower value passing therethrough to become a constant resistance.
    • 本发明通过允许施加到记录头的脉冲宽度调制信号的前沿和后沿中的至少一个或形成幅度和宽度调制脉冲,驱动半色调图像装置并实现高半色调再现, 作为用于在半色调控制下放置一个点的驱动脉冲,并且以幅度调制脉冲的脉冲宽度为单位脉冲宽度逐步改变脉宽调制。 本发明旨在通过将诸如半色调图像数据的输入数据转换为电压信号来实现高电压和高速脉冲输出以及低功耗,从而叠加具有相反极性的脉冲电压,并将所得到的信号施加到构成输出的开关电路 状态,并且还可以通过将等效的两端元件中的至少一个串联连接到互补FET驱动的各个驱动元件中的至少一个而实现高速和高电压驱动 电路中,所述等效的两端子元件各自以通过其中的一定或更高值的电流接通以显示恒定电压特性,并且通过其中通过的一定或更低值的电流变为恒定电阻。
    • 9. 发明授权
    • Hair processing agent and method for permanent waving hair
    • 头发处理剂及烫发方法
    • US08961946B2
    • 2015-02-24
    • US11792828
    • 2005-12-20
    • Akira ShibuyaHidemasa AokiMakoto SaitoMotoaki KamachiAtsushi TsuchiyaAkio Okamura
    • Akira ShibuyaHidemasa AokiMakoto SaitoMotoaki KamachiAtsushi TsuchiyaAkio Okamura
    • A61K8/46A61Q5/04A61K8/49
    • A61K8/4933A61Q5/04
    • Provided are hair processing agents capable of permanent waving hair even at a neutral to weakly acidic pH range that causes less irritation to the skin, and hair processing agents in which an unpleasant odor is masked. Hair processing agents contain at least one compound represented by the formula (2). Hair processing agents contain a compound of the formula (2) and at least one compound (ii) selected from thioglycolic acid, thiolactic acid, cysteine, acetylcysteine, cysteamine, acylcysteamine, salts thereof and ester derivatives thereof. Hair processing agents contain a compound of the formula (2), a surfactant and water, and are emulsified. Hair processing agents contain a compound of the formula (2) and a specific perfume. wherein X is a structure selected from —O—, —S—, —NH— and —NR1—; R1 is an alkyl group of 1 to 6 carbon atoms; Y is an oxygen atom or a sulfur atom; in the formula (1), Z is a divalent organic residue having at least one mercapto group; in the formula (2), R is a divalent organic residue optionally having a mercapto group; and R2 is a hydrogen atom or an alkyl group of 1 to 6 carbon atoms.
    • 提供即使在对皮肤刺激较少的中性至弱酸性pH范围也能永久挥发头发的头发加工剂,以及掩盖有令人不愉快的气味的毛发加工剂。 头发处理剂含有至少一种式(2)表示的化合物。 头发处理剂含有式(2)化合物和至少一种选自巯基乙酸,硫代乳酸,半胱氨酸,乙酰半胱氨酸,半胱胺,酰基半胱胺,其盐和其酯衍生物的化合物(ii)。 头发处理剂含有式(2)的化合物,表面活性剂和水,并被乳化。 头发处理剂含有式(2)的化合物和特定的香料。 其中X是选自-O - , - S - , - NH-和-NR 1 - 的结构。 R1是1-6个碳原子的烷基; Y是氧原子或硫原子; 在式(1)中,Z是具有至少一个巯基的二价有机残基; 在式(2)中,R是任选具有巯基的二价有机残基; R2为氢原子或碳原子数1〜6的烷基。
    • 10. 发明授权
    • Graft-versus-host disease predicting marker and use thereof
    • 移植物抗宿主病预测标记及其用途
    • US08153130B2
    • 2012-04-10
    • US12296345
    • 2007-04-05
    • Akira ShibuyaHiroshi Kojima
    • Akira ShibuyaHiroshi Kojima
    • A61K39/395
    • G01N33/573A61K39/3955A61K2039/505C07K16/2803G01N2333/91245G01N2800/245
    • A test method that provides data useful in predicting the probability of onset of acute graft-versus-host disease (GVHD) is described along with a kit for performing the method, and a pharmaceutical preparation and a molecular targeted therapy for treating or preventing GVHD. The test method includes measuring the blood DNAM-1 concentration of a patient of hematopoietic stem cell transplantation from bone marrow or the like over a period after the transplantation to provide data concerning the transition of the concentration to an abnormally high level deviating from the normal range, whereby the probability of the development of acute graft-versus-host disease is predicted, the risk of the development is estimated, or therapeutic effects after the development are evaluated. Concerning the molecular targeted therapy and pharmaceutical preparation used therefor wherein blood DNAM-1 of a GVHD patient or a graft recipient that is a possible patient is used as a target molecule, GVHD is treated or prevented by administering an anti-DNAM-1 antibody that is a neutralizing antibody.
    • 描述了提供用于预测急性移植物抗宿主病(GVHD)发病概率的数据的测试方法以及用于进行该方法的试剂盒以及用于治疗或预防GVHD的药物制剂和分子靶向治疗。 测试方法包括在移植后的一段时间内测量来自骨髓等的造血干细胞移植患者的血液DNAM-1浓度,以提供关于浓度向偏离正常范围的异常高水平转变的数据 预测急性移植物抗宿主病发展的可能性,估计发展的风险,或发展后的治疗效果。 关于其中使用的分子靶向治疗和药物制剂,其中GVHD患者的血液DNAM-1或作为可能患者的移植物接受体用作靶分子,通过施用抗-DNAM-1抗体来治疗或预防GVHD, 是中和抗体。